Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Lemery

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Clinical Pharmacology and Therapeutics|February 24, 2018
Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a DiseaseRobert N Schuck, Janet Woodcock, Issam Zineh, et al.
The Oncologist|July 1, 2021
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public HealthElaine Chang, Lorraine Pelosof, Steven Lemery, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 19, 2018
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute WorkshopPaul G Kluetz, Bindu Kanapuru, Steven Lemery, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practiceDavid J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Clinical Pharmacology and Therapeutics|February 24, 2018
Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a DiseaseRobert N Schuck, Janet Woodcock, Issam Zineh, et al.
The Oncologist|July 1, 2021
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public HealthElaine Chang, Lorraine Pelosof, Steven Lemery, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 19, 2018
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute WorkshopPaul G Kluetz, Bindu Kanapuru, Steven Lemery, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practiceDavid J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Pageof 3